InMed Pharmaceuticals is pleased to welcome the BayMedica team following the acquisition in October 2021.
Meet Chris Meiering, our VP of Commercial Operations. Chris talks about the unique start to his career in pet nutrition and how he got into the business of developing rare cannabinoids for the health and wellness sector.
Chris earned his PhD in microbiology, specializing in molecular virology, from the University of Washington and performed his post doctoral research at Stanford University.
In this article published in Gene Online September 4, 2024, reporter Bernice Lottering writes about InMed’s INM-901 Alzheimer’s disease preclinical study results and the company’s
There have been major advances in Alzheimer’s disease research and development in the past two years alone. What are those breakthroughs and what’s in development
In this video, InMed’s CEO, Eric A. Adams, explains the neuritogenesis process and how this process is essential for neuronal signaling and healthy brain functioning.
#1455 – 885 West Georgia St.
Vancouver, BC, Canada
V6C 3E8
© Copyright 2024 InMed Pharmaceuticals Inc.
"*" indicates required fields